Literature DB >> 29442376

Multiple system atrophy and apolipoprotein E.

Kotaro Ogaki1, Yuka A Martens1, Michael G Heckman2, Shunsuke Koga1, Catherine Labbé1, Oswaldo Lorenzo-Betancor1, Anna I Wernick1, Ronald L Walton1, Alexandra I Soto1, Emily R Vargas2, Henrietta M Nielsen1,3, Shinsuke Fujioka4, Takahisa Kanekiyo1, Ryan J Uitti4, Jay A van Gerpen4, William P Cheshire4, Zbigniew K Wszolek4, Phillip A Low5, Wolfgang Singer5, Dennis W Dickson1, Guojun Bu1, Owen A Ross1,6,7.   

Abstract

BACKGROUND: Dysregulation of the specialized lipid metabolism involved in myelin synthesis and maintenance by oligodendrocytes has been associated with the unique neuropathology of MSA. We hypothesized that apolipoprotein E, which is associated with neurodegeneration, may also play a role in the pathogenesis of MSA.
OBJECTIVE: This study evaluated genetic associations of Apolipoprotein E alleles with risk of MSA and α-synuclein pathology, and also examined whether apolipoprotein E isoforms differentially affect α-synuclein uptake in a oligodendrocyte cell.
METHODS: One hundred sixty-eight pathologically confirmed MSA patients, 89 clinically diagnosed MSA patients, and 1,277 control subjects were genotyped for Apolipoprotein E. Human oligodendrocyte cell lines were incubated with α-synuclein and recombinant human apolipoprotein E, with internalized α-synuclein imaged by confocal microscopy and cells analyzed by flow cytometry.
RESULTS: No significant association with risk of MSA or was observed for either Apolipoprotein E ɛ2 or ɛ4. α-Synuclein burden was also not associated with Apolipoprotein E alleles in the pathologically confirmed patients. Interestingly, in our cell assays, apolipoprotein E ɛ4 significantly reduced α-synuclein uptake in the oligodendrocytic cell line.
CONCLUSIONS: Despite differential effects of apolipoprotein E isoforms on α-synuclein uptake in a human oligodendrocytic cell, we did not observe a significant association at the Apolipoprotein E locus with risk of MSA or α-synuclein pathology.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  apolipoprotein E; genetics; multiple system atrophy; oligodendrocyte; protection

Mesh:

Substances:

Year:  2018        PMID: 29442376      PMCID: PMC5889322          DOI: 10.1002/mds.27297

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   9.698


  17 in total

1.  Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy.

Authors:  J Q Trojanowski; T Revesz
Journal:  Neuropathol Appl Neurobiol       Date:  2007-12       Impact factor: 8.090

2.  Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology.

Authors:  Shunsuke Koga; Maiko Ono; Naruhiko Sahara; Makoto Higuchi; Dennis W Dickson
Journal:  Mov Disord       Date:  2017-04-25       Impact factor: 10.338

3.  Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy.

Authors:  H R Morris; A Schrag; U Nath; D Burn; N P Quinn; S Daniel; N W Wood; A J Lees
Journal:  Neurosci Lett       Date:  2001-10-19       Impact factor: 3.046

4.  Multiple system atrophy/progressive supranuclear palsy: alpha-Synuclein, synphilin, tau, and APOE.

Authors:  H R Morris; J R Vaughan; S R Datta; R Bandopadhyay; H A Rohan De Silva; A Schrag; N J Cairns; D Burn; U Nath; P L Lantos; S Daniel; A J Lees; N P Quinn; N W Wood
Journal:  Neurology       Date:  2000-12-26       Impact factor: 9.910

5.  Apolipoprotein E e4 allele frequency in patients with multiple system atrophy.

Authors:  N J Cairns; P F Atkinson; T Kovács; A J Lees; S E Daniel; P L Lantos
Journal:  Neurosci Lett       Date:  1997-01-17       Impact factor: 3.046

Review 6.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

7.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

8.  The dementia-associated APOE ε4 allele is not associated with rapid eye movement sleep behavior disorder.

Authors:  Ziv Gan-Or; Jacques Y Montplaisir; Jay P Ross; Judes Poirier; Simon C Warby; Isabelle Arnulf; Stephanie Strong; Yves Dauvilliers; Claire S Leblond; Michele T M Hu; Birgit Högl; Ambra Stefani; Christelle Charley Monaca; Valérie Cochen De Cock; Michel Boivin; Luigi Ferini-Strambi; Giuseppe Plazzi; Elena Antelmi; Peter Young; Anna Heidbreder; Thomas R Barber; Samuel G Evetts; Michal Rolinski; Patrick A Dion; Alex Desautels; Jean-François Gagnon; Nicolas Dupré; Ronald B Postuma; Guy A Rouleau
Journal:  Neurobiol Aging       Date:  2016-10-13       Impact factor: 4.673

Review 9.  Multiple system atrophy: the application of genetics in understanding etiology.

Authors:  Monica Federoff; Lucia V Schottlaender; Henry Houlden; Andrew Singleton
Journal:  Clin Auton Res       Date:  2015-02-17       Impact factor: 4.435

10.  A genome-wide association study in multiple system atrophy.

Authors:  Anna Sailer; Sonja W Scholz; Michael A Nalls; Claudia Schulte; Monica Federoff; T Ryan Price; Andrew Lees; Owen A Ross; Dennis W Dickson; Kin Mok; Niccolo E Mencacci; Lucia Schottlaender; Viorica Chelban; Helen Ling; Sean S O'Sullivan; Nicholas W Wood; Bryan J Traynor; Luigi Ferrucci; Howard J Federoff; Timothy R Mhyre; Huw R Morris; Günther Deuschl; Niall Quinn; Hakan Widner; Alberto Albanese; Jon Infante; Kailash P Bhatia; Werner Poewe; Wolfgang Oertel; Günter U Höglinger; Ullrich Wüllner; Stefano Goldwurm; Maria Teresa Pellecchia; Joaquim Ferreira; Eduardo Tolosa; Bastiaan R Bloem; Olivier Rascol; Wassilios G Meissner; John A Hardy; Tamas Revesz; Janice L Holton; Thomas Gasser; Gregor K Wenning; Andrew B Singleton; Henry Houlden
Journal:  Neurology       Date:  2016-09-14       Impact factor: 9.910

View more
  10 in total

1.  APOE genotype regulates pathology and disease progression in synucleinopathy.

Authors:  Albert A Davis; Casey E Inman; Zachary M Wargel; Umber Dube; Brittany M Freeberg; Alexander Galluppi; Jessica N Haines; Dhruva D Dhavale; Rebecca Miller; Fahim A Choudhury; Patrick M Sullivan; Carlos Cruchaga; Joel S Perlmutter; Jason D Ulrich; Bruno A Benitez; Paul T Kotzbauer; David M Holtzman
Journal:  Sci Transl Med       Date:  2020-02-05       Impact factor: 17.956

Review 2.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 3.  APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.

Authors:  Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg
Journal:  Mol Neurodegener       Date:  2022-09-24       Impact factor: 18.879

4.  The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.

Authors:  Daniel Twohig; Elena Rodriguez-Vieitez; Sigrid B Sando; Guro Berge; Camilla Lauridsen; Ina Møller; Gøril R Grøntvedt; Geir Bråthen; Kalicharan Patra; Guojun Bu; Tammie L S Benzinger; Celeste M Karch; Anne Fagan; John C Morris; Randall J Bateman; Agneta Nordberg; Linda R White; Henrietta M Nielsen
Journal:  Acta Neuropathol Commun       Date:  2018-11-26       Impact factor: 7.578

Review 5.  α-synuclein in the pathophysiology of Alzheimer's disease.

Authors:  Daniel Twohig; Henrietta M Nielsen
Journal:  Mol Neurodegener       Date:  2019-06-11       Impact factor: 14.195

6.  Apolipoprotein E4-driven effects on inflammatory and neurotrophic factors in peripheral extracellular vesicles from cognitively impaired, no dementia participants who converted to Alzheimer's disease.

Authors:  Mohamed Raâfet Ben Khedher; Mohamed Haddad; Danielle Laurin; Charles Ramassamy
Journal:  Alzheimers Dement (N Y)       Date:  2021-01-28

Review 7.  Apolipoprotein E in Cardiometabolic and Neurological Health and Diseases.

Authors:  Jeyashree Alagarsamy; Anja Jaeschke; David Y Hui
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

8.  Assessment of APOE in atypical parkinsonism syndromes.

Authors:  Marya S Sabir; Cornelis Blauwendraat; Sarah Ahmed; Geidy E Serrano; Thomas G Beach; Matthew Perkins; Ann C Rice; Eliezer Masliah; Christopher M Morris; Lasse Pihlstrom; Alexander Pantelyat; Susan M Resnick; Mark R Cookson; Dena G Hernandez; Marilyn Albert; Ted M Dawson; Liana S Rosenthal; Henry Houlden; Olga Pletnikova; Juan Troncoso; Sonja W Scholz
Journal:  Neurobiol Dis       Date:  2019-02-21       Impact factor: 5.996

9.  Clinicopathologic and genetic features of multiple system atrophy with Lewy body disease.

Authors:  Shunsuke Koga; Fuyao Li; Na Zhao; Shanu F Roemer; Tanis J Ferman; Anna I Wernick; Ronald L Walton; Ayman H Faroqi; Neill R Graff-Radford; William P Cheshire; Owen A Ross; Dennis W Dickson
Journal:  Brain Pathol       Date:  2020-04-14       Impact factor: 6.508

Review 10.  APOE2: protective mechanism and therapeutic implications for Alzheimer's disease.

Authors:  Zonghua Li; Francis Shue; Na Zhao; Mitsuru Shinohara; Guojun Bu
Journal:  Mol Neurodegener       Date:  2020-11-04       Impact factor: 18.879

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.